Neumora Therapeutics (NMRA) Net Income towards Common Stockholders (2022 - 2026)

Neumora Therapeutics' Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$53.5 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 21.38% year-over-year to -$53.5 million; the TTM figure through Mar 2026 stood at -$222.3 million (up 13.84% YoY), while the FY2025 annual figure was -$236.9 million, up 2.83% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$53.5 million, up from -$59.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$30.9 million in Q3 2022, with the low at -$171.9 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$56.8 million (2025), against an average of -$65.0 million.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders tumbled 71.69% in 2023, then jumped 45.78% in 2024.
• Neumora Therapeutics' Net Income towards Common Stockholders stood at -$171.9 million in 2022, then soared by 36.9% to -$108.5 million in 2023, then jumped by 45.78% to -$58.8 million in 2024, then declined by 1.01% to -$59.4 million in 2025, then grew by 10.01% to -$53.5 million in 2026.
• Business Quant data shows NMRA's Net Income towards Common Stockholders at -$53.5 million in Q1 2026, -$59.4 million in Q4 2025, and -$56.8 million in Q3 2025.